|
Health and Human Services | Food
and Drug Administration | NCTR
| | EDKB Home | Database | Endocrine Disruptors | Experimental Program | Models | Publications |
|
|
|
|
Health and Human Services | Food
and Drug Administration | NCTR
| |
|
|
Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758(1997).
Dodds E, Goldberg L, Lawson W. Oestrogenic activity of alkylated stilboestrols. Nature 142:34(1938).
EDSTAC. Http://www.Epa.Gov/opptintr/opptendo/finalrpt.Htm. In: Final Report.
Gao H, Williams C, Labute P, Bajorath J. Binary-QSAR analysis of estrogen receptor ligands. in progress(1998).
Government. Endocrine disrupter testing scheme. Chem. Eng. News 79:36-37(2001).
Glass CK, Rose DW, Rosenfeld MG. Nuclear receptor coactivators. Curr. Opin. Cell Biol. 9:222-232(1997).
Gray LE, Jr. Tiered screening and testing strategy for xenoestrogens and antiandrogens. Toxicol. Lett. 102-103:677-680(1998).
Jordan VC. Designer estrogens. Sci Am 279:60-67(1998).
Katzenellenbogen JA. The structural pervasiveness of estrogenic activity. Environ. Health Perspect. 103 Suppl 7:99-101(1995).
Kavlock RJ, Daston GP, DeRosa C, Fenner-Crisp P, Gray LE, Kaattari S, Lucier G, Luster M, Mac MJ, Maczka C, Miller R, Moore J, Rolland R, Scott G, Sheehan DM, Sinks T, Tilson HA. Research needs for the risk assessment of health and environmental effects of endocrine disruptors: A report of the U.S. EPA-sponsored workshop. Environ. Health Perspect. 104 Suppl 4:715-740(1996).
Keasling H, Schueler F. The relationship between estrogenic action and chemical constitution in a group of azomethine derivatives. J. Am. Pharmac. Assoc. 39:87-90(1950).
Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrin. 138:863-870(1997).
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: The second decade. Cell 83:835-839(1995).
Miksicek RJ. Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor. J. Steroid Biochem. Mol. Biol. 49:153-160(1994).
Patlak M. A testing deadline for endocrine disrupters. Environ. Sci. Technol. 30:540A-544A(1996).
Sadler BR, Cho SJ, Ishaq KS, Chae K, Korach KS. Three-dimensional quantitative structure-activity relationship study of nonsteroidal estrogen receptor ligands using the comparative molecular field analysis/cross-validated r2-guided region selection approach. J. Med. Chem. 41:2261-2267(1998).
Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937(1998).
Stancel GM, Boettger-Tong HL, Chiappetta C, Hyder SM, Kirkland JL, Murthy L, Loose-Mitchell DS. Toxicity of endogenous and environmental estrogens: What is the role of elemental interactions? Environ. Health Perspect. 103 Suppl 7:29-33(1995).
Tanenbaum DM, Wang Y, Williams SP, Sigler PB. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc. Natl. Acad. Sci. USA 95:5998-6003(1998).
Waller CL, Oprea TI, Chae K, Park HK, Korach KS, Laws SC, Wiese TE, Kelce WR, Gray LE, Jr. Ligand-based identification of environmental estrogens. Chem. Res. Toxicol. 9:1240-1248(1996).
Wiese TE, Polin LA, Palomino E, Brooks SC. Induction of the estrogen specific mitogenic response of mcf-7 cells by selected analogues of estradiol-17 beta: A 3d QSAR study. J. Med. Chem. 40:3659-3669(1997).
